Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.11
CHE's Cash to Debt is ranked higher than
63% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. CHE: 0.11 )
CHE' s 10-Year Cash to Debt Range
Min: 0   Max: 2.78
Current: 0.11

0
2.78
Equity to Asset 0.50
CHE's Equity to Asset is ranked higher than
77% of the 307 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. CHE: 0.50 )
CHE' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.61
Current: 0.5

0.36
0.61
Interest Coverage 8.87
CHE's Interest Coverage is ranked higher than
78% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 5.04 vs. CHE: 8.87 )
CHE' s 10-Year Interest Coverage Range
Min: 1.85   Max: 12
Current: 8.87

1.85
12
F-Score: 6
Z-Score: 5.96
M-Score: -1.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.07
CHE's Operating margin (%) is ranked higher than
82% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 8.52 vs. CHE: 11.07 )
CHE' s 10-Year Operating margin (%) Range
Min: -2.6   Max: 11.56
Current: 11.07

-2.6
11.56
Net-margin (%) 6.48
CHE's Net-margin (%) is ranked higher than
82% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 4.94 vs. CHE: 6.48 )
CHE' s 10-Year Net-margin (%) Range
Min: -3.61   Max: 10.72
Current: 6.48

-3.61
10.72
ROE (%) 21.02
CHE's ROE (%) is ranked higher than
94% of the 289 Companies
in the Global Medical Care industry.

( Industry Median: 10.03 vs. CHE: 21.02 )
CHE' s 10-Year ROE (%) Range
Min: -5.58   Max: 20.6
Current: 21.02

-5.58
20.6
ROA (%) 10.61
CHE's ROA (%) is ranked higher than
93% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 3.52 vs. CHE: 10.61 )
CHE' s 10-Year ROA (%) Range
Min: -2.96   Max: 10.79
Current: 10.61

-2.96
10.79
ROC (Joel Greenblatt) (%) 163.62
CHE's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 18.24 vs. CHE: 163.62 )
CHE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12.54   Max: 189.5
Current: 163.62

-12.54
189.5
Revenue Growth (%) 11.00
CHE's Revenue Growth (%) is ranked higher than
84% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. CHE: 11.00 )
CHE' s 10-Year Revenue Growth (%) Range
Min: -19.5   Max: 42.9
Current: 11

-19.5
42.9
EBITDA Growth (%) 6.70
CHE's EBITDA Growth (%) is ranked higher than
75% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. CHE: 6.70 )
CHE' s 10-Year EBITDA Growth (%) Range
Min: -31.3   Max: 52.3
Current: 6.7

-31.3
52.3
EPS Growth (%) 5.40
CHE's EPS Growth (%) is ranked higher than
71% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 13.80 vs. CHE: 5.40 )
CHE' s 10-Year EPS Growth (%) Range
Min: -15.4   Max: 56.8
Current: 5.4

-15.4
56.8
» CHE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CHE Guru Trades in Q4 2013

John Hussman 61,000 sh (New)
Joel Greenblatt 274,224 sh (+12.61%)
John Keeley 28,910 sh (+7.03%)
Chuck Royce 1,443,220 sh (+2.12%)
Mario Gabelli 881,698 sh (+0.69%)
Richard Pzena 362,343 sh (+0.39%)
» More
Q1 2014

CHE Guru Trades in Q1 2014

Jim Simons 39,219 sh (New)
David Dreman 565 sh (New)
Jeremy Grantham 33,147 sh (New)
Joel Greenblatt 295,553 sh (+7.78%)
Chuck Royce 1,504,885 sh (+4.27%)
John Hussman 61,000 sh (unchged)
Richard Pzena 347,051 sh (-4.22%)
Mario Gabelli 823,015 sh (-6.66%)
John Keeley 22,500 sh (-22.17%)
» More
Q2 2014

CHE Guru Trades in Q2 2014

Jim Simons 82,100 sh (+109.34%)
John Hussman 125,000 sh (+104.92%)
Mario Gabelli 835,425 sh (+1.51%)
Jeremy Grantham Sold Out
David Dreman Sold Out
John Keeley 21,400 sh (-4.89%)
Chuck Royce 1,306,738 sh (-13.17%)
Richard Pzena 281,109 sh (-19%)
Joel Greenblatt 201,109 sh (-31.96%)
» More
Q3 2014

CHE Guru Trades in Q3 2014

Ken Fisher 530,910 sh (New)
Jim Simons 89,800 sh (+9.38%)
John Keeley 21,400 sh (unchged)
Richard Pzena Sold Out
Mario Gabelli 793,833 sh (-4.98%)
Joel Greenblatt 159,963 sh (-20.46%)
John Hussman 84,000 sh (-32.8%)
Chuck Royce 746,776 sh (-42.85%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-09-30 Reduce -32.8%0.3%$94.37 - $107.31 $ 106.845%84000
Richard Pzena 2014-09-30 Sold Out 0.15%$94.37 - $107.31 $ 106.845%0
Ken Fisher 2014-09-30 New Buy0.12%$94.37 - $107.31 $ 106.845%530910
Joel Greenblatt 2014-09-30 Reduce -20.46%0.05%$94.37 - $107.31 $ 106.845%159963
John Hussman 2014-06-30 Add 104.92%0.46%$83.27 - $93.03 $ 106.8421%125000
Joel Greenblatt 2014-06-30 Reduce -31.96%0.13%$83.27 - $93.03 $ 106.8421%201109
David Dreman 2014-06-30 Sold Out $83.27 - $93.03 $ 106.8421%0
John Keeley 2014-03-31 Reduce -22.17%0.01%$73.31 - $88.81 $ 106.8432%22500
David Dreman 2014-03-31 New Buy$73.31 - $88.81 $ 106.8432%565
John Hussman 2013-12-31 New Buy0.33%$66.14 - $79.93 $ 106.8445%61000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Chemed Corp

Mario Gabelli Comments on Chemed Corp. - Jan 29, 2014

Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases.

 

From Mario Gabelli (Trades, Portfolio)’s Gabelli Asset Fund fourth quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Chemed Corp

Mario Gabelli Comments on Chemed Corp.
Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.70
CHE's P/E(ttm) is ranked higher than
87% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 44.70 vs. CHE: 20.70 )
CHE' s 10-Year P/E(ttm) Range
Min: 10.7   Max: 41.64
Current: 20.7

10.7
41.64
P/B 4.20
CHE's P/B is ranked higher than
65% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 2.93 vs. CHE: 4.20 )
CHE' s 10-Year P/B Range
Min: 1.83   Max: 5.08
Current: 4.2

1.83
5.08
P/S 1.30
CHE's P/S is ranked higher than
73% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. CHE: 1.30 )
CHE' s 10-Year P/S Range
Min: 0.67   Max: 2.46
Current: 1.3

0.67
2.46
PFCF 79.10
CHE's PFCF is ranked higher than
72% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 53.33 vs. CHE: 79.10 )
CHE' s 10-Year PFCF Range
Min: 7.11   Max: 81.76
Current: 79.1

7.11
81.76
EV-to-EBIT 12.51
CHE's EV-to-EBIT is ranked higher than
90% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 24.30 vs. CHE: 12.51 )
CHE' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 124.3
Current: 12.51

6.9
124.3
PEG 2.51
CHE's PEG is ranked higher than
91% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 2.51 )
CHE' s 10-Year PEG Range
Min: 0.31   Max: 5.41
Current: 2.51

0.31
5.41
Shiller P/E 25.40
CHE's Shiller P/E is ranked higher than
88% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 2025.80 vs. CHE: 25.40 )
CHE' s 10-Year Shiller P/E Range
Min: 15.69   Max: 137.8
Current: 25.4

15.69
137.8
Current Ratio 0.96
CHE's Current Ratio is ranked higher than
63% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. CHE: 0.96 )
CHE' s 10-Year Current Ratio Range
Min: 0.57   Max: 1.88
Current: 0.96

0.57
1.88
Quick Ratio 0.92
CHE's Quick Ratio is ranked higher than
64% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. CHE: 0.92 )
CHE' s 10-Year Quick Ratio Range
Min: 0.56   Max: 1.79
Current: 0.92

0.56
1.79

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
CHE's Dividend Yield is ranked lower than
83% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 1.51 vs. CHE: 0.80 )
CHE' s 10-Year Dividend Yield Range
Min: 0.35   Max: 1.2
Current: 0.8

0.35
1.2
Dividend Payout 0.16
CHE's Dividend Payout is ranked higher than
96% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 0.16 )
CHE' s 10-Year Dividend Payout Range
Min: 0.07   Max: 11
Current: 0.16

0.07
11
Dividend growth (3y) 13.50
CHE's Dividend growth (3y) is ranked higher than
86% of the 121 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. CHE: 13.50 )
CHE' s 10-Year Dividend growth (3y) Range
Min: -42.4   Max: 35.7
Current: 13.5

-42.4
35.7
Yield on cost (5-Year) 1.93
CHE's Yield on cost (5-Year) is ranked lower than
52% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 2.10 vs. CHE: 1.93 )
CHE' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 2.9
Current: 1.93

0.85
2.9
Share Buyback Rate 6.90
CHE's Share Buyback Rate is ranked higher than
96% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. CHE: 6.90 )
CHE' s 10-Year Share Buyback Rate Range
Min: 6.9   Max: -10.2
Current: 6.9

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
CHE's Price/DCF (Projected) is ranked higher than
87% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 4.02 vs. CHE: 1.20 )
CHE' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 2.33
Current: 1.2

0.59
2.33
Price/Median PS Value 1.30
CHE's Price/Median PS Value is ranked higher than
69% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. CHE: 1.30 )
CHE' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 1.67
Current: 1.3

0.44
1.67
Price/Peter Lynch Fair Value 2.30
CHE's Price/Peter Lynch Fair Value is ranked higher than
91% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 2.30 )
CHE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.51   Max: 5.14
Current: 2.3

0.51
5.14
Earnings Yield (Greenblatt) 8.00
CHE's Earnings Yield (Greenblatt) is ranked higher than
89% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 4.60 vs. CHE: 8.00 )
CHE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 14.5
Current: 8

0.8
14.5
Forward Rate of Return (Yacktman) 13.82
CHE's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 12.92 vs. CHE: 13.82 )
CHE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -20.4   Max: 60.1
Current: 13.82

-20.4
60.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:FMS, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:CXM.Germany,
Chemed Corp was incorporated in Delaware in 1970. The Company conducts its business operations in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). VITAS Healthcare Corporation provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 109 leased and owned office and service facilities in 30 states. VITAS operate 51 programs from 154 leased facilities and 37 inpatient units in 18 states and the District of Columbia. The Company faces competition from sewer, drain and pipe cleaning, excavation and plumbing repair businesses and is fragmented, with the bulk of the industries consisting of local and regional competitors. VITAS competes with a number of national and regional hospice providers, including Gentiva Health Services, Inc., hospitals, nursing homes, home health agencies and other health care providers. The Company is subject to federal, state and local laws and regulations relating to franchising, insurance and other aspects of business.
» More Articles for CHE

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Chemed Corp. Jan 29 2014 
The Gabelli Asset Fund Shareholder Commentary - Fourth Quarter 2013 Jan 29 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
comment on CHE May 07 2013 
comment on CHE May 07 2013 
Chemed Corporation: Fundamental Stock Research Analysis Jan 29 2013 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
hospice, roto rooter Jan 11 2012 
9 Dividend Stocks Raising Their Yield On Cost Aug 15 2011 
Guru Stocks Raising Dividends: THO, ACU, KAMN, PRIM, CHE Aug 15 2011 


More From Other Websites
NYSE stocks posting largest volume increases Dec 17 2014
Chemed Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 03 2014
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30th November, 2014 Dec 02 2014
Insider Trading Alert - FIS, RP And CHE Traded By Insiders Nov 18 2014
CHEMED CORP Financials Nov 14 2014
Chemed Reports Third-Quarter 2014 Results Nov 11 2014
10-Q for Chemed Corp. Nov 07 2014
Chemed Corporation Declares Quarterly Dividend of 22 Cents Nov 07 2014
Chemed Corporation Declares Quarterly Dividend of 22 Cents Nov 07 2014
CHEMED CORP Files SEC form 10-Q, Quarterly Report Nov 05 2014
Chemed Corporation to Present at the 2014 Credit Suisse Healthcare Conference Nov 04 2014
Recent Announcements 04 Nov 2014 ANNOUNCEMENT – DISCLOSEABLE TRANSACTIONS IN RELATION TO... Nov 04 2014
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31st October, 2014 Nov 04 2014
Chemed Corp Earnings Call scheduled for 10:00 am ET today Oct 31 2014
Chemed posts 3Q profit Oct 30 2014
CHEMED CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 30 2014
Chemed Reports Third-Quarter 2014 Results Oct 30 2014
Q3 2014 Chemed Corp Earnings Release - After Market Close Oct 30 2014
Chemed To Report Third-Quarter 2014 Earnings October 30, Related Conference Call To Be Held On... Oct 17 2014
Chemed To Report Third-Quarter 2014 Earnings October 30, Related Conference Call To Be Held On... Oct 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK